|
Adenocarcinoma
|
0.700 |
AlteredExpression
|
group |
LHGDN |
Altered trafficking of Fas and subsequent resistance to Fas-mediated apoptosis occurs by a wild-type p53 independent mechanism in esophageal adenocarcinoma.
|
15680394 |
2005 |
|
Adenocarcinoma
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Although p53 was expressed more commonly in adenocarcinoma (30% of 10) and squamous carcinoma (28% of 29) than in small cell tumors (10% of 20), this could be accounted for by the smoking history.
|
8390213 |
1993 |
|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
Although all mice developed lung tumors, only 7% of lung tumors were adenocarcinomas in wild-type mice, whereas 22 and 26% of lung tumors were adenocarcinomas in p53 transgenic or K-ras heterozygous deficient mice.
|
16247446 |
2006 |
|
Adenocarcinoma
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Although many studies have investigated the frequency of p53 protein overexpression in adenocarcinomas of the esophagus or esophagogastric junction, few studies have assessed the frequency and clinical significance of p53 mutations in these tumors.
|
10674608 |
2000 |
|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
Although structural mutations in the p53 gene have been implicated in late-stage prostate cancer, little is known about the p53 response to genotoxic stress in normal human prostatic epithelial cells from which adenocarcinomas originate.
|
7543816 |
1995 |
|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
Although the number of p53 negative adenocarcinomas without metastasis was larger than the number of p53 positive tumors without metastasis, there were not clear differences between p53 positive and negative tumors with metastasis.
|
1656762 |
1991 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Although the rate of p53 mutations in pancreatic tumours is of the same order as in other adenocarcinomas (> or = 50%), an antibody response was found in only 5/78 (6.4%) sera from patients with pancreatic cancer.
|
7947080 |
1994 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Among four adenocarcinomas arising in the lowest portion of the uterine corpus, three showed integration of human papillomavirus (HPV) types 16 and/or 18 DNA, and two of them also showed p53 mutation.
|
1336492 |
1992 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Among the six hot-spot codons of TP53 gene, three codons (175, 248 and 273) were the most commonly mutated in both types of cervical cancer, one codon (249) mainly in squamous cell carcinoma and one codon (282) only in adenocarcinoma.
|
23168175 |
2013 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Amplification of 3q was associated with mutations in TP53 in adenocarcinoma.
|
21385341 |
2011 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
An increase in the NSCLC risk posed by the p53 Pro allele (versus Arg/Arg) was seen in AC compared with controls [adjusted odds ratio (OR), 1.36; 95% confidence interval (CI), 1.1-1.7] but not in SCC (adjusted OR, 1.04; 95% CI, 0.8-1.4).
|
11751390 |
2001 |
|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
Aneuploid cell populations from Barrett's adenocarcinomas have a high prevalence of 17p allelic losses, and there is substantial evidence that the target of these losses is the p53 gene.
|
8162566 |
1994 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
APC and p53 mutations in de novo colorectal adenocarcinomas.
|
8081386 |
1994 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
As to the prognosis, there were no significant differences between the p53 gene alteration-positive and -negative cases in both the younger and older groups as well as in all subjects, while a tendency of poorer prognosis was observed in K-ras gene alteration-positive cases than for the -negative ones with adenocarcinomas.
|
7715905 |
1995 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Atg7 deficiency alters progression of Braf(V600E)-driven tumors from adenomas (Braf(V600E); atg7(-/-)) and adenocarcinomas (trp53(-/-); Braf(V600E); atg7(-/-)) to benign oncocytomas that accumulated morphologically and functionally defective mitochondria, suggesting that defects in mitochondrial metabolism may compromise continued tumor growth.
|
24362353 |
2014 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Because the p53 mutation status (frequency and spectrum) of a carcinoma can provide clues to causative agents, we subclassified 113 adenocarcinomas into five cell types: hobnail, columnar/cuboidal, mixed, polygonal, and goblet (54, 23, 18, 13, and 5, respectively) and investigated relationships with p53 mutations and smoking history.
|
11106585 |
2000 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Both Ki-ras and p53 gene mutations were found in 13/31 (41.9%) of adenocarcinomas examined, while Ki-ras and p53 overexpression was detected in 19/45 (42.2%).
|
10076772 |
1998 |
|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
Both the cytometric data and the positivity of staining for p53 revealed a statistically significant increase throughout the following sequence: no dysplasia --> indefinite for dysplasia --> low grade dysplasia --> high grade dysplasia --> adenocarcinoma.
|
9708926 |
1998 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Both tumor phenotypes resulted characterized by a p.E542K point mutation in the PIK3CA gene, whereas adenocarcinoma component revealed also a TP53 Q331* homozygous stop mutation.
|
28698100 |
2017 |
|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
By contrast, mice with both alterations (Hoxb13-MYC∣Hoxb13-Cre∣Pten(Fl/Fl), hereafter, BMPC mice) developed lethal adenocarcinoma with distant metastases and widespread genome CNAs that were independent of forced disruption of Tp53 and telomere shortening.
|
26554830 |
2016 |
|
Adenocarcinoma
|
0.700 |
GeneticVariation
|
group |
BEFREE |
By immunohistochemistry, p53 mutation was detected in 67.3% of SCC and 60.3% of AC, in comparison with 9.9% in the control (P<0.001).
|
22171791 |
2013 |
|
Adenocarcinoma
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Cases of multiple synchronous adenomas showed different patterns of p53 expression but more positivity was found in adenomas from patients with a synchronous adenocarcinoma.
|
8076381 |
1994 |
|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
Cases of UDEC had mutations in genes associated with endometrial adenocarcinomas (eg, TP53, PTEN, PIK3CA) and occasionally SMARCA4, while SDUS was characterized solely by inactivating mutations in SMARCA4.
|
31567195 |
2020 |
|
Adenocarcinoma
|
0.700 |
Biomarker
|
group |
BEFREE |
Cases showing abnormal p53 accumulation tended to have a shortened survival only when the tumors were adenocarcinomas (risk ratio, 1.75; P = 0.06).
|
9815783 |
1997 |
|
Adenocarcinoma
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Cdx2, mucin (MUC) series (MUC2, MUC5AC and MUC6), p53 and E-cadherin expression in Barrett's esophagus and adenocarcinoma specimens were examined by immunostaining.
|
23382633 |
2013 |